TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17076223
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bisoprolol and enalapril with trimetasidine (70 mg/day from postmyocardial day 7-10 for 6 months)
Study: 17076223
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bisoprolol and enalapril without trimetasidine
Study: 12411847
Drug: Hypodermoclysis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypodermoclysis with 1000 ml 5% dextrose in water infusion plus 140 mEq/L sodium chloride at 42 ml/hour per day
Study: 12411847
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with subcutaneous drugs (haloperidol 2.5 mg every 4 hours and/or metoclopramide 10 mg every 4 hours)
Study: 6385678
Drug: Hydralazine (149
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (149 +/- 11 mg daily)
Study: 28678111
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Batroxobin and Tranexamic Acid (Group BT)
Study: 25576896
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of injectable powder of pure HSYA (IPPH) at doses of 25, 50, and 75 mg
Study: 25576896
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of 50 mg IPPH, once daily for 7 consecutive days
Study: 25576896
Drug: Single and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and multiple dosing of IPPH
Study: 10461765
Drug: Terazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin (1 mg)
Study: 10895397
Drug: tolcapone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolcapone (100 or 200 mg three times daily)
Study: 8644624
Drug: Chronic oral
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic oral sotalol
Study: 6378158
Drug: Phenylephrine hydrochloride
Normalized name: Phenylephrine Hydrochloride
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine hydrochloride nose drops or nasal spray
Study: 24050737
Drug: Glimepiride (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (2 mg)
Study: 21859060
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride (saline solution)
Study: 16955184
Drug: Topical morphine
Normalized name: morphine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical morphine gel 0.3%
Study: 11509270
Drug: Conventional analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional analgesia (parenteral opiates)
Study: 9928856
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of aprotinin (Group B)
Study: 7988583
Drug: Anaesthetic solution
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaesthetic solution injected into the perivascular axillary sheath (12 ml of a mixture of equal parts of 0.5% bupivacaine with 1:200,000 adrenaline and 2% lignocaine)
Study: 1102232
Drug: Butorphanol tartrate
Normalized name: Butorphanol Tartrate
DrugBank: Butorphanol (DB00611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Butorphanol tartrate (1 mg)
Study: 1102232
Drug: Butorphanol tartrate
Normalized name: Butorphanol Tartrate
DrugBank: Butorphanol (DB00611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Butorphanol tartrate (2 mg)
Study: 1102232
Drug: Butorphanol tartrate
Normalized name: Butorphanol Tartrate
DrugBank: Butorphanol (DB00611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Butorphanol tartrate (4 mg)
Study: 30630555
Drug: group rumination-focused
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: group rumination-focused cognitive-behavioural therapy (RFCBT)
Study: 21443271
Drug: Crotalidae polyvalent
Normalized name: Antivenin,crotalidae polyvalent
DrugBank: Viper antivenom (DB14114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crotalidae polyvalent immune Fab (IV administration)
Study: 15521841
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (13-15 mg/kg/day) + Mycophenolate mofetil (1000 mg b.d.)
Study: 15521841
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (13-15 mg/kg/day)
Study: 9254071
Drug: Mixed meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed meal containing 63 g fat and 150,000 IU vitamin A
Study: 1483485
Drug: Sinemet CR
Normalized name: Sinemet CR
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sinemet CR (200 mg levodopa/50 mg carbidopa)
Study: 8485018
Drug: Madopar CR
Normalized name: Madopar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Madopar CR (100 mg levodopa/25 mg benserazide)
Study: 2442994
Drug: Ethmozine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethmozine (600 to 900 mg/day in 3 equally divided doses)
Study: 2442994
Drug: Ethmozine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethmozine plus Propranolol (40 mg, 3 times daily)
Study: 2442994
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg, 3 times daily)
Study: 2442994
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Ethmozine plus Propranolol)
Study: 2442994
Drug: Ethmozine or
Normalized name: Ethmozine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethmozine or combination therapy
Study: 29543126
Drug: Suspension-training movement
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension-training movement program (6 weeks, two 1-hour sessions per week)
Study: 19337387
Drug: Salsalate (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate (4.5 g/d)
Study: 19337387
Drug: Salsalate (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate (3.0 g/d)
Study: 19337387
Drug: Salsalate (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate (maximum tolerable dose, no tinnitus)
Study: 8970352
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (LDD) 3 micrograms/kg/min
Study: 3361170
Drug: Metoclopramide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (1 mg/kg, 4 times every 2.5 hours), dexamethasone (3.8 mg, 4 times every 2.5 hours), antihistamine (10 mg, 2 times every 5 hours)
Study: 3361170
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antiemetic agents)
Study: 3361170
Drug: Combined antiemetic
Normalized name: ANTIEMETICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antiemetic agents
Study: 21984028
Drug: Clonidine 1
Normalized name: apraclonidine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 1 μg/kg IV
Study: 2127016
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) as add-on therapy
Study: 2085059
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg vitamin E (d‐alpha‐tocopherolacetate, V, n = 26)
Study: 2085059
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Diclofenac (D, n = 27)
Study: 2085059
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg vitamin E (V)
Study: 2085059
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Diclofenac (D)
Study: 492827
Drug: Pediatric telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric telephone protocols administered by health assistants
Study: 25818032
Drug: Instillation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of 5 ml 2% lidocaine gel in the urethra 5 minutes before catheterization
Study: 25818032
Drug: Lubrication of
Normalized name: Eyes Alive Lubricating
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubrication of the distal part of the catheter with 5 ml 2% lidocaine gel
Study: 11207991
Drug: Albumin infusion
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin infusion (1 g/kg bodyweight, i.v., during the first 2 h of phototherapy)
Study: 7912393
Drug: Molsidomine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine (1 mg/h intravenously for 48 h, followed by 16 mg molsidomine by mouth daily for 12 days)
Study: 7912393
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical to molsidomine treatment)
Study: 31866092
Drug: Salvage Radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage Radiation Therapy (SRT) ± Salvage Hormone Therapy (SHT) (64.8 Gy of SRT followed by 80 mg bicalutamide and LHRH agonist if BCL fails)
Study: 31866092
Drug: Salvage Hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage Hormone Therapy (SHT) (80 mg bicalutamide followed by LHRH agonist in case of BCL failure)
Study: 29116013
Drug: Dexamethasone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (40 mg intravenous injection)
Study: 21449786
Drug: Double placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double placebo (placebo injection plus childhood oral placebo)
Study: 21449786
Drug: Estrogen alone
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen alone (placebo injection plus childhood oral low-dose estrogen)
Study: 21449786
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone alone (growth hormone injection plus childhood oral placebo)
Study: 21449786
Drug: Growth hormone-estrogen
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone-estrogen (growth hormone injection plus childhood oral low-dose estrogen)
Study: 21449786
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment (vs. placebo)
Study: 21449786
Drug: Growth hormone-estrogen
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone-estrogen vs. growth hormone alone
Study: 12560406
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (5 g/d + 2 g of dextrose)
Study: 12560406
Drug: Placebo (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (7 g of dextrose)
Study: 11192131
Drug: Amprenavir (APV)
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Amprenavir (APV) in combination with 2 nucleoside reverse transcriptase inhibitors
Study: 9098860
Drug: Stimulation with
Normalized name: INM-005 (PURIFIED FAB'2 FRACTION OF EQUINE HYPERIMMUNE SERUM GENERATED FROM ANTIGENIC STIMULATION WITH THE SARS-COV2 RBD PROTEIN)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation with 0.05 TU/mL of PPD
Study: 8513853
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg diclofenac
Study: 3912335
Drug: Nimesulide 200
Normalized name: nimesulide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 200 mg suppositories
Study: 3912335
Drug: Diclofenac 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 100 mg suppositories
Study: 23982988
Drug: 12-week exercise
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week exercise therapy
Study: 21354934
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg pentazocine with 1.5 mg/kg propofol
Study: 21354934
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg pentazocine with 1.5 mg/kg propofol
Study: 18720001
Drug: Melatonin 3
Normalized name: melatonin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 3 mg daily for 30 days
Study: 18720001
Drug: Melatonin 3
Normalized name: melatonin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 3 mg daily for 8 weeks
Study: 17288677
Drug: Sertraline 50-200
Normalized name: sertraline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50-200 mg/day
Study: 12010156
Drug: Mandibular implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular implants
Study: 12010156
Drug: Maxillary implants
Normalized name: Artemisia capillaris leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxillary implants
Study: 9393427
Drug: Implants in
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants in bone quality 1
Study: 9393427
Drug: Implants in
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants in bone quality 2
Study: 9393427
Drug: Implants in
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants in bone quality 3
Study: 9393427
Drug: Implants in
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants in bone quality 4
Study: 7683190
Drug: High lipase
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: High lipase preparation
Study: 282003
Drug: Simultaneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous administration of cytosine arabinoside (Ara-C) 150 mg/m2 and methotrexate (MTX) 40 mg/m2
Study: 282003
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of cytosine arabinoside (Ara-C) 150 mg/m2 and methotrexate (MTX) 40 mg/m2
Study: 28243855
Drug: BIS-based propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BIS-based propofol dosing
Study: 28243855
Drug: LBW-based propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LBW-based propofol dosing
Study: 28243855
Drug: BIS-based and
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS-based and LBW-based propofol dosing
Study: 25844841
Drug: Low-dose infliximab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose infliximab (3.5 mg/kg)
Study: 25844841
Drug: Standard-dose infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard-dose infliximab (5 mg/kg)
Study: 15174219
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO) therapy
Study: 23820795
Drug: Intratympanic (IT)
Normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratympanic (IT) steroid injection
Study: 17159456
Drug: Olanzapine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (8 weeks treatment)
Study: 9763328
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing and oral hygiene combined with local controlled drug delivery with tetracycline fibers
Study: 9763328
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing with oral hygiene instructions
Study: 7875182
Drug: meperidine 2
Normalized name: meperidine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine 2 mg.kg‐1 (M)
Study: 7875182
Drug: meperidine 2
Normalized name: meperidine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine 2 mg.kg‐1 plus midazolam 0.05 mg.kg‐1 (M + M)
Study: 28012181
Drug: 5-aminolaevulinic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-aminolaevulinic acid (ALA) photodynamic therapy (PDT)
Study: 18594954
Drug: Heroin-assisted treatment
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin-assisted treatment
Study: 21820084
Drug: JTE-607 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTE-607 (0.1 mg/kg/h)
Study: 21820084
Drug: JTE-607 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTE-607 (0.3 mg/kg/h)
Study: 21820084
Drug: JTE-607 (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: JTE-607 (0.03 mg/kg/h)
Study: 18075221
Drug: Dressing containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dressing containing 800 mg of plant sterol (PS), 15 g daily for 12 weeks
Study: 17076934
Drug: tiapride (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: tiapride (300 mg/d)
Study: 15049438
Drug: Levosulpiride preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosulpiride preparation 1 (25 mg)
Study: 15049438
Drug: Levosulpiride preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosulpiride preparation 2 (25 mg)
Study: 8236072
Drug: PEF measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEF measurement at two hourly intervals during waking hours for one week
Study: 8236072
Drug: Bronchial challenge
Normalized name: MANNITOL BRONCHIAL CHALLENGE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchial challenge test measuring the provocative dose of methacholine producing a 20% fall in FEV1 (PD20)
Study: 3323648
Drug: i.v. immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. immunoglobulin G
Study: 31862532
Drug: Hospitals should
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospitals should provide smoking cessation treatments
Study: 29473353
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (acupuncture at five mind points + modified kidney qi decoction)
Study: 23856331
Drug: AS03-adjuvanted split
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted split virion vaccine (3.75 μg HA/AS03)
Study: 23856331
Drug: Non-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted vaccine (15 μg HA)
Study: 18386547
Drug: etoricoxib 180
Normalized name: étoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 180 mg
Study: 18386547
Drug: etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 120 mg and 180 mg
Study: 11129710
Drug: Bio-Skincare (BSC)
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-Skincare (BSC) - 1.2 g
Study: 11129710
Drug: Mosiguard towelletes
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mosiguard towelletes with 0.574 g PMD
Study: 11129710
Drug: Deet (15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deet (15% diethyl-3-methylbenzamide, Tabard lotion) - 0.5 g
Study: 8770963
Drug: Magnesium carbonate
Normalized name: Magnesium Carbonate
DrugBank: Magnesium carbonate (DB09481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium carbonate (MgCO3) at a dose of 465 +/- 52 mg/day elemental Mg
Study: 8770963
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (CaCO3) at the usual dose
Study: 2857677
Drug: Somatostatin infusion
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin infusion for 72 hours
Study: 30785624
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for BDD (CBT‐BDD)
Study: 16089135
Drug: Conventional medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medicine plus tongxinluo capsule (TXL)
Study: 16089135
Drug: Conventional medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medicine (Control Group)
Study: 10084583
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oral estradiol daily
Study: 10084583
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oral estradiol daily
Study: 31847908
Drug: 0.1% topical
Normalized name: Halog 0.1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% topical sirolimus applied for 12 weeks
Study: 31847908
Drug: Topical vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vehicle applied for 12 weeks
Study: 26265727
Drug: Efalex Active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efalex Active 50+ (1g DHA, 160 mg eicosapentaenoic acid, 240 mg Ginkgo biloba, 60 mg phosphatidylserine, 20mg d‐α tocopherol, 1mg folic acid, and 20 µg vitamin B12 per day)
Study: 22522786
Drug: Muscle strengthening
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle strengthening exercises (performed twice a week for 3 months, starting at 60% of 1MR and progressing to 85%)
Study: 15159711
Drug: Best practices
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best practices including assessment of arterial oxygenation, collection of blood cultures, timely initiation of appropriate empiric antibiotic therapy
Study: 10211597
Drug: PEIT-1 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEIT-1 (1 session with a single intranodular injection of sterile 98% ethanol)
Study: 10211597
Drug: PEIT-3 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEIT-3 (3 weekly sessions with 1 injection of sterile 98% ethanol)